Integrum AB Stock price

Equities

INTEG B

SE0009807266

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm 07:45:54 2024-03-28 am EDT 5-day change 1st Jan Change
50.2 SEK -0.59% Intraday chart for Integrum AB +0.40% +9.97%
Sales 2024 * 108M 10.05M Sales 2025 * 153M 14.28M Capitalization 931M 87.06M
Net income 2024 * 9M 842K Net income 2025 * 24M 2.24M EV / Sales 2024 * 8.51 x
Net cash position 2024 * 16M 1.5M Net cash position 2025 * 2M 187K EV / Sales 2025 * 6.08 x
P/E ratio 2024 *
-50.5 x
P/E ratio 2025 *
-50.5 x
Employees 34
Yield 2024 *
-
Yield 2025 *
-
Free-Float 57.08%
More Fundamentals * Assessed data
Dynamic Chart
Integrum Enters a Commercial agreement with AMI Technologies to introduce the OPRATM Implant System in Israel CI
Integrum AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Integrum Sells and Delivers Opratm Implant Systems to A Value of SEK 3.5 Million to Center of Excellence in Ukraine CI
Integrum AB Establishes Center of Excellence in Ukraine CI
Integrum AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Integrum AB Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data CI
Integrum AB Provides Earnings Guidance for the Second Quarter of 2023 CI
Integrum Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations CI
Integrum's Opra?? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations CI
Integrum Enters into the Turkey Market CI
Integrum Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing CI
Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI CI
Integrum Receives Unitary Patent for Neuromotus in the EU CI
Integrum AB Appoints Scott Flora as Full Board Member CI
Integrum Initiates A Strategic Review Process to Accelerate Growth CI
More news
1 day-2.08%
1 week-1.10%
Current month+3.02%
1 month+15.00%
3 months+7.27%
6 months+73.20%
Current year+8.32%
More quotes
1 week
47.60
Extreme 47.6
50.90
1 month
43.90
Extreme 43.9
54.50
Current year
37.45
Extreme 37.45
54.50
1 year
16.40
Extreme 16.4
54.50
3 years
16.40
Extreme 16.4
104.60
5 years
5.30
Extreme 5.3
104.60
10 years
5.30
Extreme 5.3
104.60
More quotes
Managers TitleAgeSince
Founder 64 97-12-31
Director of Finance/CFO - 23-05-01
Chief Operating Officer 62 23-01-31
Members of the board TitleAgeSince
Director/Board Member 67 18-12-31
Chairman 71 18-12-31
Founder 64 97-12-31
More insiders
Date Price Change Volume
24-03-28 50.2 -0.59% 2 225
24-03-27 50.5 +0.20% 21,808
24-03-26 50.4 +2.13% 11,956
24-03-25 49.35 -0.50% 17,915
24-03-22 49.6 -0.80% 13,575

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 04:49 am EDT

More quotes
Integrum AB is a Sweden-based company within healthcare sector. It provides systems for bone-anchored prostheses for individuals with amputations. The Company's solutions comprise OPRA Implant System, neural prosthetics, phantom limb pain treatment and prosthetic components. The OPRA implant system is based on osseointegration, enabling the direct connection of an artificial limb to the skeleton. The neural prosthetics technology implies ability to directly connect bionic prostheses to the patient's bone, nerves, and muscles. A method for limb pain treatment implies motor execution of the phantom limb as a treatment, which is aided by machine learning, augmented and virtual reality. The Company provides a variety of prosthetic components required to connect the OPRA Implant System to external prostheses.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Integrum AB - Nasdaq Stockholm